Atorvastatin is
in a class of medications called HMG-CoA reductase inhibitors (statins). It
works by slowing the production of cholesterol in the body. Buildup of
cholesterol and fats along the walls of the blood vessels (a process known as
atherosclerosis or hardening of the arteries) decreases blood flow and, therefore, the oxygen supply to the
heart, brain, and other parts of the body. Lowering blood levels of cholesterol
and fats may help to prevent heart disease, angina (chest pain), strokes, and
heart attacks. Atorvastatin is used with diet changes (restriction of
cholesterol and fat intake) to reduce the amount of cholesterol and certain
fatty substances in the blood. Atorvastatin
reduces cholesterol levels, but there is no evidence that the use of
atorvastatin increases longevity in those who have no existing heart disease or
whose cholesterol levels are not excessively elevated.
Caduet is a
prescription drug that combines two medicines, amlodipine besylate and
atorvastatin calcium. Lipitor
is the brand name for atorvastatin.
See natural ways to lower
cholesterol levels
using diet and supplements.
Need for CoQ10
supplement
Histol Histopathol. 2014. Does coenzyme-Q have a protective effect against atorvastatin induced myopathy? A histopathological and immunohistochemical study
in albino rats. A side effect of statins, statin-induced myopathy, which may
result from reduced muscular coenzyme Q10 levels, limits their use. The current
study investigates if supplementing with CoQ10 could ameliorate statin induced
myopathy. Atorvastatin increased the intensity of the immune-positive
reactions of cytochrome C and Bax. These changes were ameliorated by
concomitantly giving coenzyme Q10. Conclusion: CoQ10 may ameliorate atorvastatin
induced skeletal muscle injury.
Atorvastatin and Stroke - Possible increase in mortality with use
Atorvastatin is
being promoted for use after stroke, but my interpretation of the study listed
below (which was highly publicized as it reducing the risk of stroke)
leads me to believe that those who use atorvastatin either don't live longer, or
may actually die sooner. So, what's the point of wasting 150 dollars a month and incurring the possible atorvastatin side effects such as liver
damage, muscle tissue breakdown, and other health risks?
High-Dose
Atorvastatin after Stroke or Transient Ischemic Attack
2006.
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
Investigators
Pierre Amarenco, M.D. (Denis Diderot University, Paris), Julien Bogousslavsky,
M.D. (University of Lausanne, Lausanne, Switzerland), Alfred Callahan, III, M.D.
(Neurologic Consultants, Nashville), Larry B. Goldstein, M.D. (Duke University
Medical Center, Durham, N.C.), Michael Hennerici, M.D., Ph.D. (Universitat
Heidelberg, Mannheim, Germany), Henrik
Sillesen, M.D., D.M.Sc. (University of Copenhagen, Copenhagen), Lisa Simunovic,
M.S. (Pfizer, New York), Michael Szarek, M.S. (Pfizer, New York), K.M.A. Welch,
M.B., Ch.B., (Rosalind Franklin University of Medicine and Science, North
Chicago), and Justin A. Zivin, M.D., Ph.D. (University of California, San Diego)
assume full responsibility for the overall content and integrity of the article.
Editorial by Kent, D. M.
Statins reduce the incidence of strokes among patients at increased risk for
cardiovascular disease; whether they reduce the risk of stroke after a recent
stroke or transient ischemic attack (TIA) remains to be established. We randomly
assigned 4731 patients who had had a stroke or TIA within one to six months
before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100
to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary
heart disease to double-blind treatment with 80 mg of atorvastatin per day or
placebo. The primary end point was a first nonfatal or fatal stroke. Results:
The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9
mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter
(3.3 mmol per liter) among patients receiving placebo. During a median follow-up
of 5 years, 265 patients (11 percent) receiving atorvastatin and 311
patients (13 percent) receiving placebo had a fatal or nonfatal stroke. The atorvastatin
group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo
group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year
absolute reduction in the risk of major cardiovascular events was 3.5 percent. The overall mortality rate was similar, with 216 deaths in
the atorvastatin group and 211 deaths in the placebo group, as
were the rates of serious adverse events. Elevated liver enzyme values were more
common in patients taking atorvastatin. Conclusions: In patients with recent
stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin
per day reduced the overall incidence of strokes and of cardiovascular events,
despite a small increase in the incidence of hemorrhagic stroke.
Comment by Lou Mancano, M.D.
I read your Newsletter regarding the atorvastatin and stroke
study. You might comment in a future edition on the Number Needed to Treat (NNT)
analysis. The NNT is the number of patients who need to be treated in order to
prevent one additional bad outcome. It is the inverse of the Absolute Risk
Reduction (ARR). How to Calculate NNTs.
NNT = 1/ARR
ARR = [CER - EER]
where
CER = control group event rate
EER = experimental group event rate
In the statin and stroke article, the CER was 13% and the EER was 11%. Therefore
the ARR is 2%. One divided by 0.02 = 50. Therefore, one needs to treat 50
patients to avoid one stroke, meaning 49 out of 50 patients derive no benefit.
Atorvastatin side effects
Many people who take atorvastatin notice side effects such as muscle
problems and liver problems. Atorvastatin side effects reported include muscle
pain, tenderness, or weakness. Rarely, there can be flulike symptoms or
yellowing of the skin or eyes, abdominal pain, unexplained fatigue, dark colored
urine or pale colored stools. These may be early symptoms of muscle or liver
problems and are considered a serious atorvastatin side effect.
Atorvastatin may cause drug-induced liver injury and such liver injury may be followed by prolonged cholestasis and interlobular bile duct injury.
CNS Drugs. 2014. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, may cause neuropsychiatric reactions. They include behavioural alterations (severe irritability, homicidal impulses, threats to others, road rage, depression and violence, paranoia, alienation, antisocial behaviour); cognitive and memory impairments; sleep disturbance (frequent awakenings, shorter sleep duration, early morning awakenings, nightmares, sleepwalking, night terrors); and sexual dysfunction (impotence and decreased libido). Studies designed to investigate specific neuropsychiatric endpoints have yielded conflicting results. Several mechanisms, mainly related to inhibition of cholesterol biosynthesis, have been proposed to explain the detrimental effects of statins on the central nervous system. Approaches to prevent and manage such adverse effects may include drug discontinuation and introduction of dietary restrictions; maintenance of statin treatment for some weeks with close patient monitoring; switching to a different statin; dose reduction; and use of ω-3 fatty acids or coenzyme Q10 supplements. The available information suggests that neuropsychiatric effects associated with statins are rare events that likely occur in sensitive patients.
Myasthenia gravis
J Clin Neurosci. 2014. Statins can induce myasthenia gravis. The
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins,
are commonly prescribed for prevention of cardiovascular morbidity. A rare side
effect of statin medication is the induction of autoimmune illnesses, including
myasthenia gravis (myasthenia). Here we present two patients with seropositive
myasthenia that developed 4 weeks after initiation of atorvastatin, increasing
the total reported patients to seven. Reviewing recent literature we highlight
the connections between statins, auto-immunity and myasthenia. Statins may
favour T-cell phenotypes that reduce cell-mediated immunity but could increase
antibody-mediated humoral immunity.
Patient report,
testimonial, experience
I am 52, I took 10 mg daily for the past 5 years for the cholesterol control.
Due to high GGT of 93 in recent blood test, my family physician asked me to stop
taking atorvastatin for 2 weeks and took the blood test and liver ultrasound
test again, I got GGT of 69 and still in the high range. Since GGT was
improving, I attribute the high GGT to the medication. I had BMI of 26, non
alcoholic, keep swimming twice per week.
I have been reading your articles and believe I have been on atorvastatin 80 mg and cloidogrel 75mg for over 8 years. I had a heart attack w 5 stints. Since then there have been absolutely no re occurrences. I am very active and just do not want to stay on statins. I am experiencing joint pain, stiffness, lack of sex drive [not normal for me], get tired in the afternoon and loss of memory . I would like to find a natural solution or a solution that couples a temporary drug with natural supplements.
Atorvastatin does not reduce cardiovascular risk in those with diabetes
Efficacy and
safety of atorvastatin in the prevention of cardiovascular end points in
subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary
Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Diabetes Care. 2006.
Harborview Medical Center, Seattle, WA
The purpose of this study was to evaluate the effect of 10 mg of atorvastatin
versus placebo on cardiovascular disease prevention in subjects with type 2
diabetes and LDL cholesterol levels below contemporary guideline targets.
Subjects were randomly assigned to receive 10 mg of atorvastatin or placebo in a
4-year, double-blind, parallel-group study. The composite primary end point
comprised cardiovascular death, nonfatal myocardial infarction, nonfatal stroke,
recanalization, coronary artery bypass surgery, resuscitated cardiac arrest, and
worsening or unstable angina requiring hospitalization. Composite
end point reductions were not statistically significant. This result may relate
to the overall study design, the types of subjects recruited, the nature of the
primary end point, and the protocol changes required because of changing
treatment guidelines. For these reasons, the results of the Atorvastatin Study
for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent
Diabetes Mellitus (ASPEN) did not confirm the benefit of therapy.
Increase in
blood sugar and glycated hemoglobin
Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in
Hypercholesterolemic Patients
Journal of the American College of Cardiology, 2010.
We investigated whether atorvastatin might decrease insulin sensitivity and
increase ambient glycemia in hypercholesterolemic patients. Clinical trials
suggest that some statin treatments might increase the incidence of diabetes
despite reductions in low-density lipoprotein (LDL) cholesterol and improvement
in endothelial dysfunction. A randomized, single-blind, placebo-controlled
parallel study was conducted in 44 patients taking placebo and in patients given
daily atorvastatin 10, 20, 40, and 80 mg, during a 2-month treatment period.
Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol and apolipoprotein B levels after 2 months of therapy when compared with either baseline
or placebo. Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting
plasma insulin and glycated
hemoglobin levels. Atorvastatin decreased insulin sensitivity.
Despite beneficial reductions in LDL cholesterol and apolipoprotein B,
atorvastatin treatment resulted in significant increases in fasting insulin and
glycated hemoglobin levels consistent with insulin resistance and increased
ambient glycemia in hypercholesterolemic patients.
Atorvastatin does not help aortic stenosis
The popular cholesterol-reducing drug atorvastatin made by Pfizer does not prevent obstruction of the heart valve that leads to the aorta, the body's largest artery, according to June 2005 findings published in The New England Journal of Medicine. In a study conducted to determine whether the cholesterol drug atorvastatin did more than just reduce cholesterol, doctors found that atorvastatin failed to prevent obstructions that can keep the heart from pumping blood adequately. The condition, known as calcified aortic stenosis, occurs when a key heart valve narrows or becomes blocked, preventing the heart from pumping blood properly and can manifest itself in spite of reductions of cholesterol levels.
Role of coenzyme q10
Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose Atorvastatin.
J Clin Lipidol. 2008. University of Florida College of Pharmacy, Department of Pharmacy
Practice and Center for Pharmacogenomics; Gainesville, FL, USA.
Coenzyme Q10 is a provitamin synthesized via the HMG-CoA reductase
pathway, and thus may serve as a potential marker of intrinsic HMG-CoA reductase
activity. HMG-CoA reductase inhibitors (statins) decrease CoQ10, although it is
unclear whether this is due to reductions in lipoproteins, which transport
CoQ10. We evaluated whether baseline plasma CoQ10 concentrations predict the
lipid-lowering response to high-dose atorvastatin, and to what extent CoQ10
changes following atorvastatin therapy depend on lipoprotein changes.
Individuals without dyslipidemia or known cardiovascular disease received
atorvastatin 80 mg daily for 16 weeks. Blood samples collected at baseline and
after 4, 8, and 16 weeks of treatment were assayed for CoQ10. Individuals with
higher baseline CoQ10:LDL-C ratios displayed diminished absolute and percent LDL-C
reductions at 8 and 16 weeks of atorvastatin treatment. After 16 weeks of
atorvastatin, plasma CoQ10 decreased 45%. CoQ10 changes were correlated with LDL-C
and apolipoprotein B changes, but remained significant when normalized to all
lipoproteins. CoQ10 changes were not associated with adverse drug reactions.
Baseline CoQ10:LDL-C ratio was associated with the degree of LDL-C response to
atorvastatin. Atorvastatin decreased CoQ10 concentrations in a manner that was
not completely dependent on lipoprotein changes. The utility of CoQ10 as a
predictor of atorvastatin response should be further explored in patients with
dyslipidemia.
Atorvastatin
increases blood ratios of vitamin E/low-density lipoprotein cholesterol and
coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic
patients.
Nutr Res. 2010; Department of Neurology, Changhua Christian Hospital,
Changhua, Taiwan.
Statins are among the most widely used drugs in the management of
hypercholesterolemia. In addition to inhibiting endogenous cholesterol
synthesis, however, statins decrease coenzyme Q10 (CoQ10) synthesis. CoQ10 has
been reported to have antioxidant properties, and administration of drugs that
decrease CoQ10 synthesis might lead to increased oxidative stress in vivo. Our
present study examined the hypothesis that atorvastatin increased oxidative
stress in hypercholesterolemic patients due to its inhibition of CoQ10
synthesis. We investigated the effects of atorvastatin (10 mg/d) administration
for 5 months on lowering hypercholesterolemia and blood antioxidant status. The
study population included 19 hypercholesterolemic outpatients. Blood levels of
lipid and antioxidant markers, consisting of vitamin C, vitamin E, CoQ10, and
glutathione (GSH), and urinary levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG)
were examined pre- and postadministration of atorvastatin. Atorvastatin
administration resulted in a significant decrease in blood levels of total
cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, vitamin
E, and CoQ10; however, a significant increase in the ratios of vitamin E/LDL
cholesterol and CoQ10/LDL cholesterol was noted. Atorvastatin had no significant
effect on red blood cell (RBC) level of GSH and urinary 8-OHdG. The present
study provides evidence that atorvastatin exerts a hypocholesterolemic effect,
but on the basis of the urinary level of 8-OHdG and the blood ratios of vitamin
E/LDL cholesterol and CoQ10 / LDL cholesterol, has no oxidative stress-inducing
effect.
Atorvastatin and Fish Oils
Factorial study
of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics
of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Am J Clin Nutr. 2006
Disturbed HDL metabolism in insulin-resistant, obese subjects may account for an increased risk of cardiovascular disease. Fish oils and atorvastatin increase plasma HDL cholesterol, but the underlying mechanisms responsible for this change are not fully understood. We studied the independent and combined effects of fish oils and atorvastatin on the metabolism of HDL apolipoprotein A-I (apo A-I) and HDL apo A-II in obese men. Fish oils, but not atorvastatin, influence HDL metabolism chiefly by decreasing both the catabolism and production of HDL apo A-I and HDL apo A-II in insulin-resistant obese men. Addition of atorvastatin to treatment with fish oils had no additional effect on HDL kinetics compared with fish oils alone.
Email
About 5 years ago, at 50, my husband had bypass surgery (utilizing veins rather
than arteries). He has a long family history of heart issues. He is on the
"Bypass Protocol” which is Aspirin (low dose), Atenolol, Lisinopril / HCTZ, and
Atorvastaitin (generic Lipitor) and has been since the surgery. I have found
plenty of information on statin treatment on people for lower cholesterol but
not much on people post op bypass. The research I have read suggests the
atorvastatin helps with the stress on the veins and build up on the the vein
walls due to the change in pressure (the vein used on arterial blood flow). My
husband is only 56 and is struggling with server joint pain, is scheduled to
have a cataract removed next month. He is struggling to keep weight off. He does
not have diabetes, yet, but with all the research I have read, that will be
there next side effect we should expect. Because he is a young man, I am more
concerned about the side effects of the atorvastatin than the health of the
bypass veins. It feels like we are trading off vein health for quality and
quantity of life. I would hate for him to have to undergo bypass again but also
hate for him to be aging so fast in front of my eyes. His Doctors monitor his
liver function and swear the symptoms he experiences are not related to the
Lipitor. They claim the benefits far outweigh the any possible side effects. We
eat very well. Paleo but with beans and rice and have been for quite a while.
Very low sugars (natural sources). Supplement with Krill oil and Ubiquinol. We
are and have been working on improving our gut through probiotics and prebiotics.
We were using Turmeric supplements as well for a short while but could not find
a good source. He plays racquetball weekly but it is getting harder and harder
to get out of bed the next day. He understands the damage stress has on the body
and is making efforts to reduce his stress. If I could get him to join me in
yoga, that would be the bomb! So far no luck on that. I love him so much and
hate to see these drugs destroy his body in efforts to save it.